Premium
The Role of the HPA Axis in Psychiatric Disorders and CRF Antagonists as Potential Treatments
Author(s) -
Keller Paul A.,
McCluskey Adam,
Morgan Jody,
O'Connor Sean M. J.
Publication year - 2006
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.200600021
Subject(s) - neuroscience , hypothalamic–pituitary–adrenal axis , psychology , medicine , pharmacology , psychiatry , endocrinology , hormone
An overview of the links between the Hypothalamic‐Pituitary‐Adrenal (HPA) axis and psychiatric disorders is presented. The current treatments are outlined, indicating that they are insufficient to meet the needs of those that suffer from these affective disorders. Therefore, there is an urgent need for the generation of new therapeutics, in particular, against new targets. The association of the corticotrophin releasing factor (CRF) and the HPA axis indicates that CRF antagonists should be beneficial as potential therapeutics.